Angioprotektivnoe properties lowering drugs from the group of inhibitors of dipeptidyl peptidase-4

被引:0
作者
Oskola, E. V. [1 ]
Shubina, A. T. [1 ]
Karpov, Yu. A. [1 ]
机构
[1] Inst Clin Cardiol, Moscow, Russia
关键词
angioprotection; type 2 diabetes mellitus; dipeptidyl peptidase-4 inhibitors; incretins; DEPENDENT INSULINOTROPIC POLYPEPTIDE; TYPE-2; DIABETES-MELLITUS; LIPOPROTEIN-LIPASE ACTIVITY; GLUCAGON-LIKE PEPTIDE-1; NITRIC-OXIDE RELEASE; CARDIOVASCULAR SAFETY; ENDOTHELIAL FUNCTION; GLYCEMIC CONTROL; ADIPOSE-TISSUE; SITAGLIPTIN;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Diabetes mellitus (DM) is a major health problem in all developed countries. It contributes to the development of atherosclerosis and increases the risk of cardiovascular events so blood glucose level correction is essential to preventing these complications. The relatively new and promising class of anti-diabetic drugs is dipeptidyl peptidase-4 inhibitors. By improving carbohydrate metabolism, they have angioprotective effects, such as anti-inflammatory and anti-atherosclerotic ones, including atherosclerotic plaque stabilization, improve endothelial function, lower blood pressure, and reduce the severity of albuminuria, which may have clinical implications for the prevention of macrovascular complications of type 2 DM.
引用
收藏
页码:107 / 112
页数:6
相关论文
共 50 条
  • [1] Dipeptidyl peptidase-4 inhibitors: Multitarget drugs, not only antidiabetes drugs
    Zhao, Yunjuan
    Yang, Lin
    Zhou, Zhiguang
    JOURNAL OF DIABETES, 2014, 6 (01) : 21 - 29
  • [2] URATE-LOWERING EFFECTS OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS
    Panevin, Taras S.
    Zhelyabina, Olga, V
    Eliseev, Maxim S.
    Shestakova, Marina, V
    DIABETES MELLITUS, 2020, 23 (04): : 349 - 356
  • [3] Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas
    Deacon, C. F.
    Lebovitz, H. E.
    DIABETES OBESITY & METABOLISM, 2016, 18 (04) : 333 - 347
  • [4] Cardiovascular effects of dipeptidyl peptidase-4 inhibitors
    Papagianni, M.
    Tziomalos, K.
    HIPPOKRATIA, 2015, 19 (03) : 195 - 199
  • [5] Tolerability of Dipeptidyl Peptidase-4 Inhibitors: A Review
    Richard, Kathleen R.
    Shelburne, Jamie S.
    Kirk, Julienne K.
    CLINICAL THERAPEUTICS, 2011, 33 (11) : 1609 - 1629
  • [6] Dipeptidyl Peptidase-4 Inhibitors in the Elderly: More Benefits or Risks?
    Paolisso, Giuseppe
    Monami, Matteo
    Marfella, Raffaele
    Rizzo, Maria Rosaria
    Mannucci, Edoardo
    ADVANCES IN THERAPY, 2012, 29 (03) : 218 - 233
  • [7] Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Combination with Metformin
    Fass, Andrea D.
    Gershman, Jennifer A.
    ADVANCES IN THERAPY, 2013, 30 (04) : 337 - 353
  • [8] The effects of dipeptidyl peptidase-4 inhibitors on kidney outcomes
    O'Hara, Daniel V.
    Parkhill, Thomas R.
    Badve, Sunil V.
    Jun, Min
    Jardine, Meg J.
    Perkovic, Vlado
    DIABETES OBESITY & METABOLISM, 2021, 23 (03) : 763 - 773
  • [9] Dipeptidyl Peptidase-4 Inhibitors and Their Effects on the Cardiovascular System
    Solun, B.
    Marcoviciu, D.
    Dicker, D.
    CURRENT CARDIOLOGY REPORTS, 2013, 15 (08)
  • [10] Dipeptidyl peptidase-4 inhibitors as new tools for cardioprotection
    Rankovic, Marina
    Jeremic, Nevena
    Srejovic, Ivan
    Radonjic, Katarina
    Stojanovic, Aleksandra
    Glisic, Milos
    Bolevich, Stefani
    Bolevich, Sergey
    Jakovljevic, Vladimir
    HEART FAILURE REVIEWS, 2021, 26 (02) : 437 - 450